Beeinflussung von Blutgerinnung und Fibrinolyse durch Oestrogen, Gestagen und eine Oestrogen-Gestagen-Kombination
- 1 May 1976
- journal article
- Published by Springer Nature in Journal of Molecular Medicine
- Vol. 54 (9) , 431-438
- https://doi.org/10.1007/bf01470929
Abstract
Eight female subjects received a contraceptive with a low estrogen content (Neogynon®), the estrogen component (50 µg ethinylestradiol) and consecutively the gestagen component (250 µg D-Norgestrel) of the contraceptive.Keywords
This publication has 21 references indexed in Scilit:
- ANTITHROMBIN III AND THE ŒSTROGEN CONTENT OF COMBINED ŒSTRO-PROGESTAGEN CONTRACEPTIVESThe Lancet, 1972
- Hormonal contraception and thromboembolic disease: Effects of the oral contraceptives on hemostatic mechanisms: A review of the literatureJournal of Chronic Diseases, 1971
- ORAL CONTRACEPTIVES AND LOW ANTITHROMBIN-III CONCENTRATIONThe Lancet, 1970
- ORAL CONTRACEPTIVES AND LOW ANTITHROMBIN-III ACTIVITYThe Lancet, 1970
- Effects of different systemic contraceptives on blood fibrinolysisAmerican Journal of Obstetrics and Gynecology, 1970
- Progestational agents and blood coagulation. II.American Journal of Obstetrics and Gynecology, 1969
- The Coagulation Mechanism in Oral ContraceptionPublished by Wiley ,1967
- EFFECT OF $OElig;STRIOL ON PLATELET ADHESIVENESS AND FIBRINOLYSIS IN MENThe Lancet, 1966
- Effect of a progestin-estrogen oral contraceptive on blood clotting factorsMetabolism, 1965
- Gerinnungsphysiologische Schnellmethode zur Bestimmung des FibrinogensActa Haematologica, 1957